Cargando…

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer

Detalles Bibliográficos
Autor principal: Tripathy, Sambit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388337/
https://www.ncbi.nlm.nih.gov/pubmed/34465966
http://dx.doi.org/10.4103/iju.IJU_542_20
_version_ 1783742619057127424
author Tripathy, Sambit
author_facet Tripathy, Sambit
author_sort Tripathy, Sambit
collection PubMed
description
format Online
Article
Text
id pubmed-8388337
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-83883372021-08-30 The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer Tripathy, Sambit Indian J Urol Uroscan Wolters Kluwer - Medknow 2021 2021-07-01 /pmc/articles/PMC8388337/ /pubmed/34465966 http://dx.doi.org/10.4103/iju.IJU_542_20 Text en Copyright: © 2021 Indian Journal of Urology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Uroscan
Tripathy, Sambit
The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
title The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
title_full The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
title_fullStr The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
title_full_unstemmed The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
title_short The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
title_sort aramis trial: why darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
topic Uroscan
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388337/
https://www.ncbi.nlm.nih.gov/pubmed/34465966
http://dx.doi.org/10.4103/iju.IJU_542_20
work_keys_str_mv AT tripathysambit thearamistrialwhydarolutamideisbetterthanapalutamideandenzalutamideinnonmetastaticcastrationresistantprostatecancer
AT tripathysambit aramistrialwhydarolutamideisbetterthanapalutamideandenzalutamideinnonmetastaticcastrationresistantprostatecancer